ProQR Therapeutics (PRQR) Competitors

Akebia Therapeutics (NASDAQ:AKBA) and ProQR Therapeutics (NASDAQ:PRQR) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

Do institutionals and insiders hold more shares of AKBA or PRQR?

33.9% of Akebia Therapeutics shares are owned by institutional investors. Comparatively, 32.7% of ProQR Therapeutics shares are owned by institutional investors. 3.0% of Akebia Therapeutics shares are owned by insiders. Comparatively, 8.4% of ProQR Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Does the media prefer AKBA or PRQR?

In the previous week, Akebia Therapeutics had 2 more articles in the media than ProQR Therapeutics. MarketBeat recorded 4 mentions for Akebia Therapeutics and 2 mentions for ProQR Therapeutics. ProQR Therapeutics' average media sentiment score of 0.74 beat Akebia Therapeutics' score of 0.70 indicating that ProQR Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Akebia Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ProQR Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts rate AKBA or PRQR?

Akebia Therapeutics presently has a consensus price target of $6.75, suggesting a potential upside of 73.97%. ProQR Therapeutics has a consensus price target of $8.00, suggesting a potential upside of 238.98%. Given ProQR Therapeutics' higher possible upside, analysts clearly believe ProQR Therapeutics is more favorable than Akebia Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Akebia Therapeutics	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.20
ProQR Therapeutics	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.13

Is AKBA or PRQR more profitable?

Akebia Therapeutics has a net margin of -24.51% compared to ProQR Therapeutics' net margin of -157.04%. Akebia Therapeutics' return on equity of 0.00% beat ProQR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Akebia Therapeutics	-24.51%	N/A	-18.92%
ProQR Therapeutics	-157.04%	-53.49%	-22.07%

Which has more volatility & risk, AKBA or PRQR?

Akebia Therapeutics has a beta of 0.88, suggesting that its stock price is 12% less volatile than the S&P 500. Comparatively, ProQR Therapeutics has a beta of 0.36, suggesting that its stock price is 64% less volatile than the S&P 500.

Which has better valuation & earnings, AKBA or PRQR?

ProQR Therapeutics has lower revenue, but higher earnings than Akebia Therapeutics. Akebia Therapeutics is trading at a lower price-to-earnings ratio than ProQR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Akebia Therapeutics	$160.18M	6.36	-$69.41M	-$0.21	-18.48
ProQR Therapeutics	$20.46M	12.14	-$30.04M	-$0.35	-6.74

Summary

Akebia Therapeutics beats ProQR Therapeutics on 9 of the 16 factors compared between the two stocks.